Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Add" for 药明康德 (WuXi AppTec) [6][53]. Core Insights - The report highlights the recent approval of new drugs, including 埃诺格鲁肽注射液 (Energulutide Injection), which is the first of its kind approved for adult type 2 diabetes patients [16]. - The report emphasizes the importance of the recent policies from the National Medical Security Administration aimed at enhancing the medical insurance landscape, which is expected to improve service levels and create development opportunities in the industry [14]. - The report notes significant growth in product revenues for companies like 信达生物 (Innovent Biologics) and 康方生物 (CanSino Biologics), indicating a positive trend in the sector [31][32]. Industry News - The National Medical Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance field, which is expected to enhance service levels and create industry development opportunities [14]. - The Ministry of Industry and Information Technology, along with seven other departments, released a plan for the high-quality development of the traditional Chinese medicine industry from 2026 to 2030, aiming to strengthen the entire industry chain [15]. - The report mentions that in 2025, the employee medical insurance personal account had a total of 4.64 billion person-times, with a total amount of 68.77 billion yuan [15]. Company Announcements - 信达生物 (Innovent Biologics) reported a strong revenue growth of approximately 45% year-on-year for 2025, with a significant increase in Q4 revenue due to new drugs being included in the national medical insurance directory [31]. - 康方生物 (CanSino Biologics) granted exclusive commercialization rights for 伊喜宁® (Evinacumab) to 济川药业 (Jichuan Pharmaceutical), receiving an upfront payment of 80 million yuan [32]. - 恒瑞医药 (Hengrui Medicine) has had several drug applications accepted by the FDA and NMPA, indicating ongoing progress in its product pipeline [33]. Market Review - The report notes a decline in major indices, with the SW Pharmaceutical and Biological sector down by 0.97% during the week of January 30 to February 5, 2026 [45]. - The overall industry P/E ratio as of February 5, 2026, was reported at 51.01 times, with a valuation premium of 261% relative to the CSI 300 index [47]. Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring companies involved in small nucleic acids and AI applications [53].

Core Insights - The article discusses the competitive landscape of the IL-4Rα monoclonal antibody market, highlighting Dupixent's dominance and the emerging challenges from new entrants [2][11][15] Group 1: Dupixent's Market Position - Dupixent, developed by Sanofi, has achieved significant sales milestones, with Q4 2025 revenue reaching €4.246 billion (approximately $5.085 billion), marking a 32.2% year-over-year increase [1] - Since its FDA approval in March 2017, Dupixent has rapidly become a leading drug in the autoimmune space, with sales surpassing $2.2 billion in its first year and exceeding $2 billion in 2019 [3][5] - The drug's success is attributed to its strategic targeting of the IL-4Rα pathway, which is crucial in mediating type 2 inflammation, and its innovative VelocImmune® technology that enhances safety and efficacy [6][7] Group 2: Competitive Landscape - The approval of Connoa's Suplizumab in September 2024 marks the second IL-4Rα monoclonal antibody to enter the market, intensifying competition against Dupixent [12] - Other candidates, including Leideqi (CBP-201) and Tairiqi, are in the NDA stage, indicating a growing pipeline of competitors that could challenge Dupixent's market share [13][14] - The emergence of these new IL-4Rα monoclonal antibodies suggests a shift from a "one-player" market to a more competitive environment, with multiple players vying for market share [11][15] Group 3: Future Outlook - The article suggests that while Dupixent remains a strong player, its growth may face challenges due to the increasing number of competitors and the saturation of its core indications [15] - The competitive dynamics in the IL-4Rα space are expected to evolve, with a focus on differentiation strategies and the expansion of indications being critical for maintaining market position [15]

2月6日，生猪养殖龙头牧原股份（02714.HK）正式登陆港交所，成功实现"A+H"两地上市，与宁德时代（03750.HK）、恒瑞医药（01276.HK）等企业一同 完成这一资本布局。 数据显示，港股上市首日，牧原股份平开后小幅走高，截至发稿，其H股报40.70港元/股，上涨4.36%。 从日前招股阶段的表现来看，香港公开发售方面，牧原股份获5.88倍认购，公开发售的发售股份最终数目为2739.52万股股份，占发售股份总数的约10%。合 共接获约21268份有效申请，受理申请数目约21268份。 | 香港公開發售 | | | --- | --- | | 有效申請數目 | 21,268 | | 受理申請數目 | 21.268 | | 認購額 | 5.88倍 | | 觸發回補機制 | 不適用 | | 香港公開發售項下初步可供認購的發售股份數目 | 27.395.200 | | 從國際發售重新分配的發售股份數目 | 0 | | 香港公開發售項下最終發售股份數目 | 27.395.200 | | 香港公開發售項下最終發售股份數目佔全球發售項下最終發售 股份數目的百分比 | 10% | | | 图源：公告 | 此外，国 ...

Investment Rating - The report assigns an "Overweight" rating to the industry, indicating a positive outlook compared to the market benchmark [3][37]. Core Insights - The recovery in innovative drug financing and business development (BD) is signaling the industry's entry into a repair cycle, with clinical Contract Research Organization (CRO) demand supported by improved funding conditions [3][6]. - The number of Investigational New Drug (IND) applications has increased, reflecting a substantial recovery in research and development activities, with a notable rise in the approval rates for innovative drugs [3][22][26]. - The global regulatory focus has shifted from risk aversion to efficiency, which is expected to accelerate clinical trial processes and enhance the demand for CRO services [3][29]. Summary by Sections 1. Recovery in Innovative Drug Financing and BD - The primary market financing amount has rebounded, with a total of approximately 79.53 billion RMB raised in the first three quarters of 2025, marking a 22.4% year-on-year increase [6][9]. - The financing structure has improved, with a shift from early-stage investments to later-stage clinical projects, indicating a more substantial commitment to projects with clear clinical pathways [9][10]. - China has become a significant source of projects for multinational corporations (MNCs), with the total amount of transactions involving Chinese assets reaching 39.4 billion USD, accounting for about 37.4% of global transaction amounts [16][18]. 2. Dual Recovery in Applications and Reviews - The number of IND applications has shown a significant increase, with 1,878 applications in 2025, reflecting a 13.34% year-on-year growth [22][23]. - The approval rates for INDs and New Drug Applications (NDAs) have improved, with a 96.53% approval rate for INDs and an 86.87% rate for NDAs, indicating a more efficient review process [26][28]. 3. Intensified Global Competition and AI-Driven Changes - The FDA is promoting continuous trials and the application of AI in clinical execution, which is expected to enhance efficiency in clinical trials [29][30]. - Leading CROs are leveraging AI to transform their delivery models, moving from project-based human delivery to platform-based digital delivery, thereby improving operational efficiency and client retention [30].

Group 1 - The core viewpoint of the news highlights the positive performance of the Chinese pharmaceutical and medical device innovation index, with significant gains in specific stocks and a new development plan for traditional Chinese medicine [1] - The China Securities Regulatory Commission and eight other departments have issued a plan to promote the high-quality development of traditional Chinese medicine, aiming to approve a batch of innovative traditional Chinese medicines and cultivate ten major traditional Chinese medicine products by 2030 [1] - The overall funding congestion in the innovative drug sector has slightly decreased compared to Q2, with some funds temporarily withdrawing from innovative drugs, while the medical device sector remains stable and is expected to attract more investment [1] Group 2 - The China Medical and Medical Device Innovation Index (931484) includes 30 listed companies with good profitability and growth potential, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index account for 63.9% of the total index, including companies like WuXi AppTec, Mindray Medical, and Hengrui Medicine [2]

Market Overview - The three major indices experienced a decline with the Shanghai Composite Index falling below 4100 points, and market turnover significantly reduced to 2.1 trillion yuan. The consumer and banking sectors showed notable gains [1] - The gold market saw a drop, leading to significant sell-offs in precious metals like Zijin Mining. The performance of AMD in the US market negatively impacted the storage giants, causing a collective downturn in the semiconductor and AI application sectors [1] - As the long Spring Festival holiday approaches, the Ministry of Commerce plans to host a "Happy Shopping Spring Festival" event, boosting activity in the consumer sector. Seven films are scheduled for release during the festival, with Moutai experiencing a surge in demand, leading to a crash in its app [1] Institutional Insights - Overall, the three major indices collectively retreated, with 3715 stocks declining. The market environment appears balanced on the surface but shows internal fragmentation, with short-term style switches. Trend investing is less effective, and a more suitable approach is to reduce individual stock risk exposure [2] - In a high-volatility environment, the focus should shift from storytelling to capturing market price and capital behavior. Attention is particularly drawn to the impact of precious metals and futures volatility on liquidity [2] Market Sentiment and Strategy - The recent low point in the market is likely the bottom before the New Year, with decreasing volatility in domestic and international futures markets suggesting a potential increase in risk appetite for equities. The market is expected to continue with weak main lines and strong rotations [3] - Investors are advised to allocate part of their positions to the suppressed CSI 300 or SSE 50 heavyweight stocks as a base, while also engaging in rotation and selection strategies. The technology sector, particularly AI applications and semiconductor investments, is highlighted as a potential opportunity [3] ETF Performance - As of February 5, 2026, the SSE 180 Index fell by 0.64%, with mixed performance among constituent stocks. Notable gainers included Transsion Holdings (+5.20%) and Haitian Flavoring (+4.63%), while major losers included Daqo New Energy (-8.30%) and Zhongtian Technology (-7.29%) [4] - The SSE 180 ETF saw a turnover of 1.05% with a trading volume of 625,100 yuan. Over the past year, the ETF's average daily trading volume was 1,557,500 yuan, indicating significant growth [4] Tracking Accuracy - The SSE 180 ETF has a tracking error of 0.023% over the past six months, closely following the SSE 180 Index, which consists of 180 large-cap, liquid stocks from the Shanghai market [5] - The top ten weighted stocks in the SSE 180 Index account for 24.85% of the index, with significant contributions from Zijin Mining, Kweichow Moutai, and China Ping An [5][6]

证券分析师 022-28451618 SAC NO：S1150511010016 cuijian@bhzq.com 晨会纪要（2026/02/06） 市场处于震荡整固阶段，结构性行情将是重点——A 股市场 2026 年 2 月投资 策略报告 行业研究 关注年报业绩催化与创新药械产业链——医药生物行业 2 月投资策略展望 崔健 渤海证券研究所晨会纪要（2026.02.06） 宏观及策略研究 晨会纪要（2026/02/06） 宏观及策略研究 市场处于震荡整固阶段，结构性行情将是重点——A 股市场 2026 年 2 月投资策略报告 请务必阅读正文之后的声明 渤海证券股份有限公司具备证券投资咨询业务资格 1 of 6 要 宋亦威（证券分析师，SAC NO：S1150514080001） 云计算提价印证高景气，AI 应用迎来多点催化——计算机行业 2 月投资策略 展望 证 券 研 究 报 告 晨 会 纪 严佩佩（证券分析师，SAC NO：S1150520110001） 靳沛芃（研究助理，SAC NO：S1150124030005） 1、宏观方面 2026 年年初，出口端在结构优化、产品竞争优势以及经贸环境改善的支撑下将 ...

Core Viewpoint - The report from CITIC Securities on January 26, 2023, set a target price of 1322 CNY for Baillie Tianheng (688506.SH), suggesting a potential increase of 367% from its current price of 282.83 CNY, which has drawn significant attention online [1][17]. Group 1: Company Performance and Financials - Baillie Tianheng reported a net loss of 11 billion CNY for 2025, which was a 130% year-on-year decrease in net profit, contradicting CITIC's earlier prediction of a loss of 7.6 billion CNY [17][19]. - The company has experienced substantial research and development expenditures, with figures of 3.75 billion CNY, 7.46 billion CNY, 14.43 billion CNY, and 10.39 billion CNY for the first half of 2025, indicating that R&D costs have significantly outpaced revenue [22][23]. - The company’s revenue for 2022 was 701.83 million CNY, with projections of 560.42 million CNY for 2023 and 5.82 billion CNY for 2024, reflecting a substantial increase in expected revenue [23]. Group 2: Product Development and Market Position - Baillie Tianheng's drug Iza-bren (BL-B01D1) has entered a priority review process for a new indication, which is expected to enhance the company's market position significantly [19][21]. - The company has a total of 17 clinical-stage candidates, with 6 currently undergoing trials in the United States, showcasing its robust pipeline of innovative drugs [21]. - The strategic partnership with BMS, valued at 8.4 billion USD, represents one of the largest global licensing deals in the ADC field, further solidifying Baillie Tianheng's market presence [21]. Group 3: Market Sentiment and Analyst Predictions - The target price of 1322 CNY, which was later removed from the latest report, indicates a highly optimistic outlook from CITIC Securities, despite the company's recent financial struggles [19][20]. - The stock price of Baillie Tianheng has increased over tenfold since its issuance price of 24.7 CNY in January 2023, raising questions about its sustainability at current levels [27]. - Historical context suggests skepticism regarding CITIC's predictions, as similar past forecasts have not materialized positively, such as the case with Moutai [24].

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, aimed at treating atopic dermatitis, marking a significant development as no similar drugs have been approved domestically or internationally [1] Company Summary - The company has invested 40.1 million yuan in the SHR-1894 project [1]

Group 1 - Kailong High-Tech is focusing on the embodied intelligence sector, launching the "Huilingjia" series of robots and dexterous intelligent detection equipment, which are still in the market development stage and have not yet generated revenue [2] - Wuzhou New Spring plans to establish a joint venture with Zhongzhe High-Speed Rail, focusing on the research and manufacturing of high-end equipment bearings, with a registered capital of 60 million yuan [3] - GCL-Poly has not yet received any orders in the "space photovoltaic" sector, which remains in the exploratory stage, and this has not materially impacted the company's performance [5] Group 2 - Guoxuan High-Tech plans to raise no more than 5 billion yuan through a private placement, with proceeds allocated to a 20GWh power battery project and other related initiatives [4] - Xingsheng Zhitu confirmed that its operations are normal and there are no undisclosed significant matters [6] - Nanjin Mining intends to invest 30 million USD to acquire a 10% stake in Eagle Valley Gold Company, pending regulatory approvals [7] Group 3 - Lixun Precision plans to engage in foreign exchange derivatives trading for up to one year, with a cumulative limit of 4.9 billion USD [8] - Heng Rui Medicine's HR091506 tablet application for market approval has been accepted by the National Medical Products Administration, targeting long-term treatment for hyperuricemia in gout patients [11] - Wen's shares reported a revenue of 4.698 billion yuan from pork sales in January 2026, a decrease of 11.17% month-on-month [12] Group 4 - Yingjixin reported a net profit of 177 million yuan for 2025, a year-on-year increase of 42.81% [13] - Xibu Muye's fresh milk production in January 2026 was 3,076.65 tons, a year-on-year decrease of 2.54% [15] - Alibaba Health's shareholding in Shuyupingmin has decreased to 5.39% following a series of share reductions [16] Group 5 - Jiangfeng Electronics plans to acquire control of Kaide Quartz, with stock resuming trading on February 6 [17] - Runze Technology is planning to issue convertible bonds to acquire minority stakes in Runhui Technology, leading to a stock suspension starting February 6 [18] - Tianqimo is planning to purchase shares of Dongshi Automotive Technology Group, resulting in a stock suspension from February 6 [19] Group 6 - ST Lifang's stock has surged by 314.93% from January 20 to February 5, leading to a suspension for risk assessment [20][21]